Research programme: proto oncogene proteins c-akt inhibitors - DeveloGen

Drug Profile

Research programme: proto oncogene proteins c-akt inhibitors - DeveloGen

Latest Information Update: 24 Sep 2010

Price : $50

At a glance

  • Originator DeveloGen
  • Class Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 Sep 2010 DeveloGen has been acquired by Evotec AG
  • 21 Jun 2007 Teva Pharmaceutical Industries granted an exclusive worldwide license to DeveloGen's protein kinase B technology for the treatment of cancer
  • 14 Jun 2004 Peptor has been acquired by, and merged into, DeveloGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top